» Articles » PMID: 26215712

Oral Cavity and Oropharyngeal Squamous Cell Carcinoma--an Update

Overview
Publisher Wiley
Specialty Oncology
Date 2015 Jul 29
PMID 26215712
Citations 420
Authors
Affiliations
Soon will be listed here.
Abstract

Oral cavity squamous cell carcinoma (OC-SCC) is the most common malignancy of the head and neck (excluding nonmelanoma skin cancer). Recent trends have shown a dramatic rise in the incidence of oropharyngeal squamous cell carcinoma (OP-SCC), with a marked increase in lesions related to human papillomavirus infection. This update presents the latest evidence regarding OC-SCC and OP-SCC. In particular, the authors compare and contrast tumors at these two sites with respect to epidemiology, etiopathogenesis, clinicopathologic presentation, clinical assessment, imaging, management, and prognosis. It is important for clinicians to be aware of differences between OC-SCC and OP-SCC so that appropriate patient education and multidisciplinary care can be provided to optimize outcomes.

Citing Articles

The Role of Yes-Associated Protein in Inflammatory Diseases and Cancer.

Zhong B, Du J, Liu F, Sun S MedComm (2020). 2025; 6(3):e70128.

PMID: 40066231 PMC: 11892025. DOI: 10.1002/mco2.70128.


Correlation Between Periodontal Disease and Oral, Oropharyngeal, and Parapharyngeal Cancers.

Daily Z, Mohammed N, Mohammed S, Hussein H Clin Cosmet Investig Dent. 2025; 17:147-158.

PMID: 40027983 PMC: 11869753. DOI: 10.2147/CCIDE.S512557.


EpCAM Signaling in Oral Cancer Stem Cells: Implications for Metastasis, Tumorigenicity, and Therapeutic Strategies.

Chang C, Tsai C, Tsai F, Chu T, Hsu P, Kuo C Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996844 PMC: 11854592. DOI: 10.3390/cimb47020123.


Unique clinical features and prognostic risk factors of oral squamous cell carcinoma in patients under 30 years old.

Cheng H, Wu Y, Yu Z Clin Oral Investig. 2025; 29(3):150.

PMID: 39984782 DOI: 10.1007/s00784-025-06213-8.


Nobiletin and 5‑demethylnobiletin ameliorate hypopharyngeal squamous cell carcinoma by suppressing TGF‑β‑mediated epithelial‑mesenchymal transition.

Gutierrez-Venegas G, Rosas-Martinez M Oncol Lett. 2025; 29(4):176.

PMID: 39975956 PMC: 11836556. DOI: 10.3892/ol.2025.14922.